GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical ResearchSeptember 5, 2023
Together, the companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics.
GenNext Technologies, Inc., provider of novel instrumentation, software, and services for structural biology research, revealed their agreement to co-market a robust, full-solution workflow for Hydroxyl Radical Protein Footprinting (HRPF) studies with SCIEX, a global leader in life science analytical technologies. The announcement was made today at the California Separation Science Society combined Mass Spectrometry and Higher Order Structure (CASSS MS/HOS) meetings.
The agreement leverages each company’s leading products to create a state-of-the art structural biology workflow to advance higher order structure analysis of biotherapeutics. GenNext’s Flash Oxidation (Fox®) Protein Footprinting System performs covalent labeling of biotherapeutic products. Mass spectrometry analysis is then performed on the ZenoTOF 7600 system from SCIEX, followed by high resolution data analysis to be done by GenNext’s FoxWare® Data Processing Software.
GenNext’s Fox System easily performs higher order structure studies for biotherapeutic discovery and development that previously required complicated, expensive, and dangerous lasers or beamline sources. Coupling the Fox System to the ZenoTOF 7600 system enables the acquisition of high-resolution mass spectrometry data. The powerful MS/MS sensitivity and enhanced ion fragmentation technology of the ZenoTOF 7600 system allows for localization of challenging PTMs and more comprehensive understanding of protein structure.
Data generated from the workflow collaboration will be showcased during the CASSS MS meeting during the poster presentation “Improving TNFα’s Epitope Identification with Residue Level Hydroxyl Radical Protein Footprinting using the ZenoTOF 7600 system,” presented by Emily Chea, of GenNext Technologies.
“We are proud to link the GenNext brand with SCIEX, a top-tier innovator of first-in-class, high-resolution MS equipment,” said Scot Weinberger, CEO of GenNext Technologies. “The combined power of both companies’ products will improve therapeutic efficacy and safety, substantially accelerate biotherapeutic development, and benefit the many millions of people who depend on these drugs.”
“The ZenoTOF 7600 system is a strong fit within the GenNext HOS analysis workflow,” states Jose Castro-Perez, Senior Director Global Market Development at SCIEX. “Novel fragmentation with Electron Activate Dissociation (EAD) technology on the system adds another dimension for structural characterization, providing information with the speed and accuracy needed to confidently accelerate biopharmaceutical and biosimilar development.”
This optimized GenNext/SCIEX workflow will make the study of protein HOS more accessible, impactful, and transformative for biopharmaceutical researchers.
About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.
SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.
Today, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.
That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.
Drug Discovery & Development